REDWOOD CITY, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present clinical data from three anti-cancer stem cell clinical programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting to be held November 18-21, 2014 in Barcelona, Spain.
Among the presentations will be clinical data from OncoMed's anti-Notch1 (OMP-52M51) solid tumor clinical trial. Interim results from the Phase 1a study have been selected for an oral plenary session presentation. Additional data will be presented from the demcizumab (anti-DLL4, OMP-21M18) and tarextumab (anti-Notch2/3, OMP-59R5) programs.
|November 19, 2014 – ANTI-NOTCH1|
|Plenary Session 2 - 13:50 pm – 15:20 pm CET|
|"Safety and early evidence of activity of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors"|
|Presenting author: Amita Patnaik, M.D., South Texas Accelerated Research Therapeutics (START)|
|November 19, 2014 – DEMCIZUMAB|
|Poster Session: Preclinical Models|
|"Pre-clinical and clinical activity of Anti-DLL4 (demcizumab) in combination with gemcitabine plus nab-paclitaxel in pancreatic cancer"|
|Abstract # 166; Poster Board 160|
|Presenting author: Manuel Hidalgo, M.D., Ph.D., CNIO-CIOCC-START|
|November 21, 2014 – TAREXTUMAB|
|Poster Session: Molecular Targeted Agents II|
|"Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TRXT) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)"|
|Abstract #465, Poster Board 037|
|Presenting author: Ann Kapoun, Ph.D., OncoMed Pharmaceuticals|
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), anti-Notch1 (OMP-52M51), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28), which target key cancer stem cell signaling pathways including Notch and Wnt. In addition, OncoMed has filed an Investigational New Drug (IND) application for its anti-DLL4/anti-VEGF bispecific antibody (OMP-305B83) and plans to file an IND application for anti-RSPO3 (OMP-131R10) in early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
CONTACT: Investor Contact: OncoMed Pharmaceuticals Shari Annes Investor Relations (650) 888-0902 firstname.lastname@example.org Media Inquiries: BCC Partners Michelle Corral or Karen L. Bergman (415) 794-8662 or (650) 575-1509 email@example.com or firstname.lastname@example.org
Source:OncoMed Pharmaceuticals, Inc.